Compare MICC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MICC | CYTK |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | Netherlands | United States |
| Employees | 16571 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 7.6B |
| IPO Year | N/A | 2004 |
| Metric | MICC | CYTK |
|---|---|---|
| Price | $14.18 | $66.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | N/A | ★ $89.26 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $5.51 | $7.37 |
| Revenue Next Year | $4.17 | $310.19 |
| P/E Ratio | $28.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.96 | $29.31 |
| 52 Week High | $19.93 | $70.98 |
| Indicator | MICC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 56.57 |
| Support Level | $14.06 | $59.12 |
| Resistance Level | $15.94 | $67.93 |
| Average True Range (ATR) | 0.28 | 2.12 |
| MACD | 0.03 | 0.13 |
| Stochastic Oscillator | 19.39 | 52.14 |
The Magnum Ice Cream Co NV is a spinoff from Unilever, pure-play in manufacturing and selling a broad portfolio of ice-cream brands. TMICC ice-cream portfolio includes Magnum, Ben and Jerrys, Cornetto and the Heart brand. The company is organised into three geographic regions (i) Europe and ANZ, (ii) Americas, and (iii) AMEA.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.